Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 7276 to 7290 of 8202 results

  1. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued [GID-TAG232]

  2. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued [GID-TA10126]

  3. Liposomal vincristine for treating Philadelphia chromosome-negative acute lymphoblastic leukaemia after two therapies [ID954]

    Discontinued [GID-TA11181]

  4. Masitinib for previously treated moderate Crohn's disease [ID1239]

    Discontinued [GID-TA11188]

  5. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued [GID-TA11205]

  6. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued [GID-TA10836]

  7. Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]

    Discontinued [GID-TA10768]

  8. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued [GID-TA10465]

  9. Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]

    Discontinued [GID-TA10875]

  10. Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]

    Discontinued [GID-TA10625]

  11. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

    Discontinued [GID-TA10617]

  12. Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]

    Discontinued [GID-TA10634]

  13. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued [GID-TA10585]

  14. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued [GID-TA10492]